Q-omics provides the consensus-scored TTC21B profile across patient tissues and cancer cell-line models. TTC21B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TTC21B is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, TTC21B RNA expression shows 21,735 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KIRC as cancer lineages where TTC21B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TTC21B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TTC21B survival associations across molecular data types. TTC21B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (8) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TTC21B RNA expression–survival associations across cancer types. High TTC21B expression shows unfavorable associations in ACC, KIRP, LIHC and HNSC, but favorable associations in KIRC and UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TTC21B RNA expression.
This table summarizes TTC21B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TTC21B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TTC21B shows lower tumor expression in KICH and THCA and higher tumor expression in KIRC, LIHC, CHOL and HNSC. The KIRC box plot shows higher TTC21B RNA expression in tumor versus normal tissue (log2 FC = +0.659, t-test p < 0.001).
This table shows molecular features associated with TTC21B in patient tissues and cancer cell lines. In patient samples, TTC21B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TTC21B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
